MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

Search

Bristol-Myers Squibb Co.

Deschisă

SectorSănătate

47.5 -2.24

Rezumat

Modificarea prețului

24h

Curent

Minim

46.95

Maxim

48.84

Indicatori cheie

By Trading Economics

Venit

-1.1B

76M

Vânzări

442M

12B

P/E

Medie Sector

14.05

57.333

EPS

1.67

Randament dividend

5.04

Marjă de profit

0.616

Angajați

34,100

EBITDA

-1.9B

2.6B

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+18.22% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

5.04%

2.63%

Data viitoare de dividende

1 mai 2025

Următoarea dată ex-dividende

4 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-21B

100B

Deschiderea anterioară

49.74

Închiderea anterioară

47.5

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Bristol-Myers Squibb Co. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 apr. 2025, 11:32 UTC

Câștiguri

Bristol Myers Squibb Swings to Profit in 1Q, Increases Fiscal Year Guidance

11 mar. 2025, 10:13 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

11 mar. 2025, 10:13 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

24 apr. 2025, 21:24 UTC

Top știri
Câștiguri

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 apr. 2025, 14:15 UTC

Top știri
Câștiguri

Bristol Myers Squibb Shares Sink Despite Better-than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 apr. 2025, 12:37 UTC

Market Talk
Câștiguri

Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk

24 apr. 2025, 11:17 UTC

Câștiguri

Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance

24 apr. 2025, 11:13 UTC

Top știri
Câștiguri

Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance -- Barrons.com

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb: Raised 1Q Rev Outlook Reflecting Strong Performance of Growth Portfolio, Better-Than-Expected 1Q Legacy Portfolio Sales and Favorable Impact of About $500M Related to Forex Rates >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb Latest 1Q Includes Acquired IPRD Charge of $188M >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q U.S. Revenue Fell 7% to $7.87B >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb: Guidance Revisions Include Estimated Impact of Current Tariffs on U.S. Products Shipped to China, but Do Not Account for Any Potential Pharmaceutical Sector Tariffs >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 16% to $5.56B >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Opdivo, Breyanzi, Reblozyl and Camzyos and Reflects Strong Early U.S. Launch of Cobenfy >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q Adjusted Gross Margin 73.1% >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q International Revenue Fell 2% to $3.33B >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb: Legacy Portfolio Rev Decline Driven by Continued Generic Impact on Revlimid, Pomalyst, Sprycel and Abraxane, as Well as Impact From U.S. Medicare Part D Redesign >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 20% to $5.64B >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q Adj EPS $1.80 >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb Raises 2025 View To Rev $45.8B-$46.8B Vs Prior View $45.5B >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q Gross Margin 72.9% >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb Raises 2025 View To Adj EPS $6.70-Adj EPS $7.00 Vs Prior View $6.55-$6.85 >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q Rev $11.2B >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q EPS $1.20 >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol-Myers Squibb 1Q Adj EPS $1.80 >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol-Myers Squibb 1Q Rev $11.2B >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol-Myers Squibb 1Q Net $2.46B >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol-Myers Squibb Sees FY Adj EPS $6.70-Adj EPS $7.00 >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol-Myers Squibb 1Q EPS $1.20 >BMY

14 mar. 2025, 09:30 UTC

Top știri

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

Comparație

Modificare preț

Bristol-Myers Squibb Co. Așteptări

Obiectiv de preț

By TipRanks

18.22% sus

Prognoză pe 12 luni

Medie 57.56 USD  18.22%

Maxim 70 USD

Minim 36 USD

În baza a 19 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBristol-Myers Squibb Co. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

19 ratings

5

Cumpărare

13

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

47.54 / 48.82Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Bearish Evidence

Termen lung

Strong Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.